Literature DB >> 33414414

Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4+ Treg cells in ovarian cancer cells microenvironment.

Rui Xu1,2, Ming Wu1,2, Shuna Liu1,2, Wenwen Shang1,2, Rong Li1,2, Juan Xu1,2, Lei Huang1,2, Fang Wang3,4.   

Abstract

Immunotherapy is expected to become the most promising new treatment for ovarian cancer owing to its immunogenicity. However, immunosuppression in the tumor microenvironment is a major obstacle to the efficacy of tumor therapy. Studies have found different metabolism ways of regulatory T cells (Tregs) in the cancer environment may be related to the immunosuppression and Toll-like receptor 8 (TLR8) can reverse the suppression function of Tregs. But it is still unclear that if the TLR8-mediated function reversal is associated with the change of glucose metabolism of Tregs. It was found that the positive expression rates of Glut1, HIF-1α, and Ki67 in CD4+ Treg cells of OC were significantly higher than that in benign ovarian tumor and HC, and also significantly higher than that in CD4+ Teffs of OC. What's more, compared with CD4+ Teff group, CD4+ Tregs highly expressed seven genes and three proteins related to glucose metabolism and had higher levels of glucose uptake and glycolysis. After activating TLR8 signal of CD4+ Tregs, the proliferation level of naive CD4+ T cells was higher than that of the control group. At the same time, the expression levels of eight genes and five proteins related to glucose metabolism in CD4+ Treg cells with TLR8 activated were decreased and levels of glucose uptake and glycolysis were also lower. Furthermore, TLR8 signaling also downregulated the mTOR pathway in CD4+ Tregs. CD4+ Tregs pretreated with 2-deoxy-d-Glucose (2-DG) and galloflavin also attenuated the inhibition of Teffs proliferation. Although CD4+ Tregs pretreated with 2-DG and galloflavin before activating TLR8 signal had no significant difference compared with the group only treated with inhibitors, which suggested TLR8-mediated reversal of CD4+ Treg cells inhibitory function in ovarian cancer cells co-cultured microenvironment had a causal relationship with glucose metabolism.

Entities:  

Year:  2021        PMID: 33414414      PMCID: PMC7790820          DOI: 10.1038/s41419-020-03272-5

Source DB:  PubMed          Journal:  Cell Death Dis            Impact factor:   8.469


  29 in total

Review 1.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation.

Authors:  Sophia Y Lunt; Matthew G Vander Heiden
Journal:  Annu Rev Cell Dev Biol       Date:  2011       Impact factor: 13.827

Review 2.  Regulation of T cell activation by TLR ligands.

Authors:  Hans-Heinrich Oberg; Matthias Juricke; Dieter Kabelitz; Daniela Wesch
Journal:  Eur J Cell Biol       Date:  2011-02-03       Impact factor: 4.492

Review 3.  Regulation of T cell immunity by cellular metabolism.

Authors:  Zhilin Hu; Qiang Zou; Bing Su
Journal:  Front Med       Date:  2018-08-16       Impact factor: 4.592

Review 4.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

5.  Differential effects of 2-deoxy-D-glucose on in vitro expanded human regulatory T cell subsets.

Authors:  Naoki Tanimine; Sharon K Germana; Martin Fan; Keli Hippen; Bruce R Blazar; James F Markmann; Laurence A Turka; Bhavana Priyadharshini
Journal:  PLoS One       Date:  2019-06-06       Impact factor: 3.240

6.  Signaling through the adaptor molecule MyD88 in CD4+ T cells is required to overcome suppression by regulatory T cells.

Authors:  Dominik Schenten; Simone A Nish; Shuang Yu; Xiting Yan; Heung Kyu Lee; Igor Brodsky; Lesley Pasman; Brian Yordy; F Thomas Wunderlich; Jens C Brüning; Hongyu Zhao; Ruslan Medzhitov
Journal:  Immunity       Date:  2014-01-16       Impact factor: 31.745

7.  Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.

Authors:  Valerie A Gerriets; Rigel J Kishton; Marc O Johnson; Sivan Cohen; Peter J Siska; Amanda G Nichols; Marc O Warmoes; Aguirre A de Cubas; Nancie J MacIver; Jason W Locasale; Laurence A Turka; Andrew D Wells; Jeffrey C Rathmell
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

8.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.

Authors:  Chih-Hao Chang; Jing Qiu; David O'Sullivan; Michael D Buck; Takuro Noguchi; Jonathan D Curtis; Qiongyu Chen; Mariel Gindin; Matthew M Gubin; Gerritje J W van der Windt; Elena Tonc; Robert D Schreiber; Edward J Pearce; Erika L Pearce
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 9.  Mechanisms of foxp3+ T regulatory cell-mediated suppression.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

Review 10.  Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges.

Authors:  Ilenia Pacella; Silvia Piconese
Journal:  Front Immunol       Date:  2019-08-27       Impact factor: 7.561

View more
  13 in total

1.  Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Authors:  Linda Hertlein; Thomas Kolben; Aurelia Vattai; Nadine Kremer; Sarah Meister; Susanne Beyer; Lucia Keilmann; Anna Hester; Mina Temelkov; Helene Heidegger; Elisa Schmoeckel; Mirjana Kessler; Sven Mahner; Udo Jeschke
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-05       Impact factor: 4.553

Review 2.  Immunometabolism - The Role of Branched-Chain Amino Acids.

Authors:  Berkay Yahsi; Gurcan Gunaydin
Journal:  Front Immunol       Date:  2022-06-23       Impact factor: 8.786

Review 3.  Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1.

Authors:  Laure Chardin; Alexandra Leary
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

4.  Significance of TEAD Family in Diagnosis, Prognosis and Immune Response for Ovarian Serous Carcinoma.

Authors:  Xinxin Ren; Xiang Wang; Bi Peng; Qiuju Liang; Yuan Cai; Kewa Gao; Yongbin Hu; Zhijie Xu; Yuanliang Yan
Journal:  Int J Gen Med       Date:  2021-10-27

5.  Identification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes.

Authors:  Xiaoyan Shen; Xiao Gu; Ruiqiong Ma; Xiaoping Li; Jianliu Wang
Journal:  Front Cell Dev Biol       Date:  2022-03-17

6.  Integrative analyses of hub genes and their association with immune infiltration in adipose tissue, liver tissue and skeletal muscle of obese patients after bariatric surgery.

Authors:  Kemin Yan; Pengyuan Zhang; Jiewen Jin; Xin Chen; Hongyu Guan; Yanbing Li; Hai Li
Journal:  Adipocyte       Date:  2022-12       Impact factor: 3.553

Review 7.  Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy.

Authors:  Yin Qianmei; Su Zehong; Wang Guang; Li Hui; Gaojian Lian
Journal:  Immunol Res       Date:  2021-07-24       Impact factor: 2.829

Review 8.  Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.

Authors:  Xin Lian; Kailin Yang; Renliang Li; Maomao Li; Jing Zuo; Bohao Zheng; Wei Wang; Ping Wang; Shengtao Zhou
Journal:  Mol Cancer       Date:  2022-01-21       Impact factor: 27.401

9.  Attenuation of PITPNM1 Signaling Cascade Can Inhibit Breast Cancer Progression.

Authors:  Zihao Liu; Yu Shi; Qun Lin; Wenqian Yang; Qing Luo; Yinghuan Cen; Juanmei Li; Xiaolin Fang; Wen G Jiang; Chang Gong
Journal:  Biomolecules       Date:  2021-08-25

10.  Curcumin analog GO-Y030 boosts the efficacy of anti-PD-1 cancer immunotherapy.

Authors:  Takashi MaruYama; Shuhei Kobayashi; Hiroyuki Shibata; WanJun Chen; Yuji Owada
Journal:  Cancer Sci       Date:  2021-10-19       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.